Collegium Pharmaceutical, Inc. provided full year 2019 guidance for Xtampza ER revenues, Nucynta Franchise revenues, and total operating expenses. Xtampza ER revenue for 2019 is estimated to be between $95 million and $105 million. Nucynta Franchise revenue for 2019 is estimated to be between $200 million and $210 million.